Squarepoint’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,746
Closed -$373K – 4711
2026
Q2
$373K Sell
11,746
-3,688
-24% -$109K ﹤0.01% 3660
2026
Q1
$465K Buy
15,434
+46
+0.3% +$1.49K ﹤0.01% 3377
2025
Q4
$534K Buy
+15,388
New +$543K ﹤0.01% 3160
2025
Q3
– Sell
-10,714
Closed -$336K – 4639
2025
Q2
$336K Buy
+10,714
New +$333K ﹤0.01% 3601
2025
Q1
– Sell
-69,954
Closed -$2.06M – 4973
2024
Q4
$2.06M Sell
69,954
-2,114
-3% -$66.8K ﹤0.01% 2384
2024
Q3
$2.24M Sell
72,068
-1,698
-2% -$61.8K ﹤0.01% 1988
2024
Q2
$2.5M Buy
73,766
+70,648
+2,266% +$3.6M ﹤0.01% 1875
2024
Q1
$203K Buy
+3,118
New +$214K ﹤0.01% 3614
2023
Q4
– Sell
-4,738
Closed -$246K – 4232
2023
Q3
$246K Sell
4,738
-1,528
-24% -$90.4K ﹤0.01% 3287
2023
Q2
$376K Sell
6,266
-12,764
-67% -$729K ﹤0.01% 2823
2023
Q1
$941K Buy
19,030
+5,696
+43% +$320K ﹤0.01% 1940
2022
Q4
$761K Buy
13,334
+7,734
+138% +$435K ﹤0.01% 2021
2022
Q3
$263K Buy
+5,600
New +$267K ﹤0.01% 2556

Other funds holding IMCR

Squarepoint's IMCR Position: Q3 2026 in Review

Squarepoint sold out of Immunocore (IMCR) in Q3 2026, closing a stake of 11,746 shares — an estimated $373K sold.

Squarepoint first reported a position in IMCR in Q3 2022 and held it in 13 quarters. The position peaked at $2.5M in Q2 2024. 55 funds tracked by Wall St. Rank hold IMCR as of Q3 2026.

  • Squarepoint reported no remaining Immunocore position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 11,746 Immunocore shares in Q3 2026, an estimated $373K.
  • Squarepoint first reported a position in Immunocore in Q3 2022 and held it in 13 quarters.
  • Squarepoint's Immunocore position peaked at $2.5M in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Immunocore as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.